AU7882291A - Novel synthetic grf analogs - Google Patents
Novel synthetic grf analogsInfo
- Publication number
- AU7882291A AU7882291A AU78822/91A AU7882291A AU7882291A AU 7882291 A AU7882291 A AU 7882291A AU 78822/91 A AU78822/91 A AU 78822/91A AU 7882291 A AU7882291 A AU 7882291A AU 7882291 A AU7882291 A AU 7882291A
- Authority
- AU
- Australia
- Prior art keywords
- ala
- peptide
- leu
- composition
- grf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- -1 Phe Chemical compound 0.000 claims description 25
- 102000018997 Growth Hormone Human genes 0.000 claims description 23
- 108010051696 Growth Hormone Proteins 0.000 claims description 23
- 239000000122 growth hormone Substances 0.000 claims description 22
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 17
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 15
- KFGRVLINLVVMJA-MITYVQBRSA-N chembl440262 Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 KFGRVLINLVVMJA-MITYVQBRSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 108010056001 somatotropin releasing hormone (1-29) Proteins 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Chemical group OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical group OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 6
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 4
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- XKCWNEVAXQCMGP-RXMQYKEDSA-N (2R)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid Chemical compound CN(CCC[C@@H](N)C(O)=O)C(N)=N XKCWNEVAXQCMGP-RXMQYKEDSA-N 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 3
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 claims description 3
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010000599 Acromegaly Diseases 0.000 claims description 2
- 206010013883 Dwarfism Diseases 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000003068 pituitary dwarfism Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 101710142969 Somatoliberin Proteins 0.000 description 30
- 102100022831 Somatoliberin Human genes 0.000 description 30
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 27
- 238000006467 substitution reaction Methods 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 229920005989 resin Polymers 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 230000036515 potency Effects 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- 239000005556 hormone Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000001817 pituitary effect Effects 0.000 description 8
- DMBKPDOAQVGTST-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-GFCCVEGCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000003578 releasing effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical class C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 2
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- CTXPLTPDOISPTE-YPMHNXCESA-N (2s,3r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)[C@@H](C)OCC1=CC=CC=C1 CTXPLTPDOISPTE-YPMHNXCESA-N 0.000 description 1
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- BKQQPCDQZZTLSE-UHFFFAOYSA-N 2-amino-3-naphthalen-1-ylpropanoic acid;hydrochloride Chemical compound Cl.C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 BKQQPCDQZZTLSE-UHFFFAOYSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 description 1
- 101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910019142 PO4 Chemical class 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000003295 arcuate nucleus Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000035252 development of secondary sexual characteristics Effects 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Luminescent Compositions (AREA)
Description
NOVEL SYNTHETIC GRF ANALOGS
1. FIELD OF THE INVENTION
The present invention relates to novel peptides having therapeutic utility. More specifically, the invention relates to peptide analogs of the naturally occurring peptide, growth hormone-releasing factor (GRF). The invention also relates to therapeutic compositions
containing these peptides, and therapeutic methods using these peptides to stimulate the production of growth hormone in vivo.
2. BACKGROUND OF THE INVENTION
Growth hormone (GH or somatotropin) is a 191- amino acid peptide which is secreted by the anterior
pituitary. Growth hormone itself does not actually promote growth directly but acts by simulating the production of one of the many true growth factors such as the somatomedins produced by the liver. The ultimate effects of growth hormone are widespread however. On a gross level, this hormone affects the skeleton, connective tissue, muscles and viscera. On a molecular level, the metabolic effects of growth hormone and somatomedins include stimulation of nucleic acid and protein synthesis, induction of positive nitrogen balance, stimulation of lipolysis, and a decrease in urea excretion.
Inadequate levels of growth hormone in children causes retardation of growth, epiphyseal development and bone age. It also causes retarded development of secondary sexual characteristics. Additional effects of growth hormone deficiency include impaired larynx development, delayed gonadal maturation, and hypoglycemia. These effects can all be reversed with normal levels of growth hormone.
The production of growth hormone is under the control of both releasing and inhibitory influences located in the hypothalamus. The primary releasing influence is growth hormone releasing factor (GRF or GHRH), which is produced primarily in the arcuate nucleus of the
hypothalamus, and is transported to the pituitary by portal circulation. However, other cells of the body such as pancreatic tumor cells, may also produce this hormone.
Growth hormone releasing factor in humans is a peptide 44 amino acids in length of which the first 29 contain the full biological activity. Similar peptides have also been isolated from cow, rat, sheep and pig, and their sequences identified (Esch et al., Biochem. Biophys. Res. Commun.
117:772, 1983).
The discovery of the sequence of GRF has provided a physiologically natural means for treating individuals with growth hormone deficiencies. Substantial efforts have been devoted to development of synthetic analogs of GRF in the hope that such analogs will be more efficient in causing release of growth hormone.
Efforts at creating new substitutions have focused on the N-terminal portion of the molecule,
particularly residues 1-29, in which the biological activity lies. Various substitutions in one or more of the amino acid residues have been shown to be effective in increasing the potency of the synthetic peptides relative to that of the natural peptide. One current approach in peptide design generally has been to explore modifications which will enhance the amphiphilic secondary structure of the peptide
(De Grado et al., J. Am. Chem. Soc. 103:679-686, 1981); Mue et al., J. Am. Chem. Soc. 105:4100-4102, 1983). Certain peptide hormones, i.e., those in which one face of the molecule has preferentially hydrophobic residues, while the other face contains a primarily hydrophilic domain, may have their activity enhanced by optimization of this amphiphilic
character. GRF has been noted as having substantial amphiphilic potential, based on observations of its binding to single bilayer phospholipid vesicles, and formation of a monolayer at the air-water interface (Kaiser et al., Science
223:249-255, 1984).
A number of attempts to alter GRF secondary
.structure have been reported in the literature. For
example. Lance et al. (Biochem. Biophys. Res. Comm. 119:265- 1984) attempted to build conformational restriction into the
N-terminus of the molecule by replacement of L-amino acids in positions 1, 2 and 3 (Tyr1, Ala2, Asp3) with their D- isomers. It was found that each of the D-analogs was more active than the native peptide. Subsequent studies extended this approach to positions 4, 5, 6, 7 and 8. Substitutions at positions 5, 6, and 7 resulted in substantial loss of activity, whereas D-substitution at position 4 retained similar activity and at position 8 increased activity (Coy et al., J. Med. Chem 28:181-185, 1985).
Further attempts to modify the secondary
structure of the basic GRF molecule have focused on
attempting to enhance the proposed amphiphilicity at certain other points on the molecule. For example, Tou et al., (Biochem. Biophys. Res. Comm. 139:763-770, 1986) noted the predicted positions of α-helicity on the GRF (1-29)
molecule, and modified certain regions of the molecule by substituting certain amino acids in the 13-29 region as well as in positions 6-10 in which a β-turn is expected to exist.
Replacement of Ser at position 9 with an Ala residue (a
"good α-helix former") was said to favor an extended helical conformation. All peptides created with this pattern exhibited enhanced activity relative to the native GRF.
It has now been surprisingly discovered that the substitution of L-Ala, or equivalent amino acid residues, at position 8 of the native molecule brings about an enormous increase in the growth hormone releasing activity of
peptides so modified. Although other substitutions at the number 8 position have previously been suggested (see e.g.
U.S. Patent No. 4,518,586, in which D-Arg, Ser, and D-Ser are substituted; U.S. Patent No. 4,689,318, in which Ser,
Asn, Thr or Gin are substituted); U.S. Patent No. 4,626,523, in which D-Arg or D-Lys are substituted) no one has proposed the use of L-Ala at this position. Indeed, Saito et al.
(Biochem. Biophys. Res. Comm. 149:531-537, 1987) substituted a D-Ala at this position, and found a substantial decrease in activity. Thus, the enhancement observed with the present specific substitution is particularly surprising.
3. SUMMARY OF THE INVENTION
The present invention relates to a group of novel peptides which are analogues of the native hormone GRF. The novel hormones are characterized by substitution of the Asn normally at the number 8 position in the native molecule with amino acids which are conducive to α-helix formation.
Specifically, the invention relates to peptides comprising the formula: R1 - R2 - R3 - Ala - lle - Phe - R7 - R8 - R9 -
R10 - Arg - R12 - R13 - R14 - R15 - Gln - R17 - R18 - Ala - Arg - R21 - Leu - R23 - R24 - R25 - R26 - R27 - R28 - R29 wherein R1 is des-amino-Tyr, or A-R1 , in which A is lower alkyl, lower cycloalkyl, benzyl or lower acyl and R1 is Tyr,
D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His, or D-His with or without a CαMe or NαMe substituent
R2 is Ala, D-Ala, D-NMA, or D-Arg;
R3 is Asp or D-Asp;
R7 is Thr, Aib, NO2, Leu, Trp, β-Nal, or p-X-Phe, in which
X = H, F, Cl, Br, NO2, or Me;
R8 is Ala, Aib, Leu, Trp, β-Nal, or p-X-Phe, in which X is H, F, Cl, Br, NO2, or Me;
R9 is Ser, Ala , Aib , Leu, Trp , β-Nal or p-X-Phe , in which X is H, F, Cl, Br, NO2 , or Me
R10 is Tyr or D-Tyr
R12 and R21 are Lys, Arg, or Nξ-B-Lys, in which B is lower alkyl or cycloalkyl, and may be the same or different R13 is lie or Val
R14 is Leu or D-Leu
R15 Gly, Ala, Leu, Asn, Gin or Aib
R17 is Leu or D-Leu
R18 is Tyr or Ser
R23 is Leu or d-Leu
R24 His or Gln
R25 is Glu, Asp, D-Glu or D-Asp
R26 is lle or Leu
R27 is Met, D-Met, Ala, Nle, lle, Leu, Nva, or Val
R28 is Asn, Ser or des R28
R29 is Arg, D-Arg or des R29;
and pharmaceutically acceptable salts thereof.
In a preferred embodiment, R8 is Ala; in a particularly preferred embodiment, R8 and R15 are Ala, and most preferably, R8, R9, and R15 are Ala. A particularly effective peptide is formed when R8, R9, and R15 are Ala, and R2 is D-Ala.
Although the formula stated above contains 29 amino acid residues, it will be understood by those skilled in the art that this represents the active portion of the molecule, and that addition of further amino acid residues to the C-terminus of the sequence will not affect the efficacy. Additions bringing the total up to 44 residues, as are present in the native GRF molecule, may be made without effect. Since these amino acids are not essential to activity, their identity is not critical; they may be the
same as in the natural GRF sequence, or reasonable
equivalents. Such alternate substitutions are found in, for example U.S. Patent Nos. 4,626,523 and 4,728,726.
The invention also provides compositions comprising a growth hormone-releasing effective amount of the peptides/salts described above in combination with apharmaceutically acceptable carrier. Also provided is a method of stimulating release of growth hormone by
administration of a composition of the invention to an individual in need of such treatment. Such a method is useful in the treatment of physiological conditions in which release of a growth hormone would be expected to be of benefit. A method of stimulating growth in healthy animals is also provided which comprises administering the
compositions of the present invention to such animals.
In an alternate embodiment, a particularly effective GRF receptor antagonist is produced by combining the specified substitutions at the 8, 9, or 15 positions with a substitution of D-Arg in the R2 position. Such peptides inhibit the activity of endogenous GRF, and therefore in turn prevent the release of growth hormone.
Thus, also provided are therapeutic compositions comprising a GRF-antagonistic effective amount of such a peptide, in combination with a pharmaceutically acceptable carrier as well as methods for inhibiting release of growth hormone by administering these compositions to an individual in need of such treatment.
4. ABBREVIATIONS
The following abbreviations are used throughout the specification and claims.
Ala Alanine
Arg Arginine
Asn Asparagine
Cys Cysteine
Gln Glutamine
Gly Glycine
His Histidine
Ile Isoleucine
Leu Leucine
Lys Lysine
Met Methionine
Phe Phenylalanine
Pro Proline
Ser Serine
Thr Threonine
Trp Tryptophan
Tyr Tyrosine
Val Valine
Aib α-amino butyric acid
des-amino-Tyr [beta(para-hydroxyphenyl)propionyl]Nle norleucine
Nva norvaline
β-Nal β-naphthylalanine
D-NMA D-alanine substituted with methyl at the alpha-amino group
BOC t-butyloxycarbonyl
Bzl benzyl
Tos P-toluenesulfonyl
2-Cl-Z 2-chlorobenzyloxycarbonyl
2-Br--Z 2-bromobenzyloxycarbonyl
chx cyclohexyl
In all cases in which isomeric forms of an amino acid exist, where no letter precedes a named residue, the naturally occurring L-isomer is intended. Also, unless a specific C-terminus substituent is noted, both the -OH (free acid) and -NH2 (amide) forms of the peptide are
contemplated.
Also, as used herein, the terms "lower" in "lower alkyl" "lower acyl" and "lower cycloalkyl" refers to C 3-4, and "cycloalkyl" is C 3-6. 5. DETAILED DESCRIPTION OF THE INVENTION
The peptides of the present invention are analogues of native GRF which exhibit greater potency than the natural hormone in releasing growth hormone. The increase in potency of these analogues is believed to be due to an enhancement in the α-helical properties of the N-terminal portion of the GRF molecule. Although it has previously been shown that enhancement of the amphiphilic α-helical properties of the C-terminal region results in increased potency of the peptides, it was not known how such
modification on the N-terminus would affect the activity of the molecule. The present results show that an unexpected increase in potency is obtained by substitution at position 8 in GRF [1-29] with amino acid residues having properties which tend to increase α-helicity. Among the amino acids in this category are Ala, Aib, Leu, Trp, β-Nal, or p-X-Phe, in which X is H, F, Cl, Br, NO2, or Me. Most preferably, R8 is
Ala. Analogues in which the only modification of the GRF
[1-29] sequence is substitution of Ala8 for Asn8 have a potency of at least 4 times that of the native molecule in vitro (Table 1). Substitution at position 15 of Ala, Leu,
Asn, Gin, or Aib, preferably Ala, results in even greater increase in potency, up to about 5 times that of native GRF in vitro. A further favorable modification is the
substitution at position 9 of one of the same preferred
residues used at position 8. The combination of these substitutions at the 8, 9, and 15 position, particularly when they are all Ala substituents, enhances the potency, and when combined with Glu25 and Leu26,27, activity is increased to 33 times that of the native GRF molecule.
It has previously been disclosed that the substitution of D-Ala at the 2 position results in increased activity of GRF [1-29]. In a particularly preferred embodiment of this invention, this substitution is combined with one or more of the 8, 9, or 15 substitutions to produce a highly potent GRF analogue having up to 49 times the activity of native GRF in vitro.
For enhancement of GRF antagonist activity, the proposed substitutions at the 8 and/or 9 and/or 15
positions, with peptides having Arg at the 2 position are particularly effective. Although the use of the Arg2 substitution has previously been reported to result in GRF antagonist activity, the proposed combinations result in even greater antagonistic activity, up to 10 times that of the D-Arg2 substitution alone.
5.1. METHOD OF PREPARATION
The preparation of the peptides of the present invention can be accomplished by any of the known methods for peptide synthesis. A preferred method is solid phase synthesis such as described by Merrifield (J. Am. Chem. Soc. 85:2149, 1963). In this method, construction of the peptide begins at the C-terminus; an amino-protected amino acid is coupled, by known methods, to an appropriate resin, such as a chloromethylated resin, a benzhydryl-amine resin or a methylbenzhydrylamme resin. Once coupling has occurred, deprotection of the terminal amino acid is performed in accordance with techniques well known to those skilled in the art. A typical deprotection medium comprises
trichloroacetic acid, either alone or in combination with
methylene chloride. The remaining protected amino acids of the desired sequence are added successively in the
appropriate order to the solid phase, and coupled to the preceding amino acid. Common coupling agents are
carbodrimide derivatives, such as dicyclohexylcarbodiimide and diisopropylcarbodiimide. Alternately, several aminoacids may be coupled to each other before being added to the solid phase synthesizer. When the sequence has been
completed, the entire peptide is cleaved from the resin, and may be purified by routine procedures in the art, such as
HPLC, or other chromatographic techniques.
5.2. PHARMACEUTICAL COMPOSITIONS
The synthetic peptides will often be used
therapeutically in the form of their pharmaceutically acceptable salts, such as acid addition salts and metal complexes; such salts include hydrochloride, hydrobromide, sulfate, acetate, maleate, benzoate, citrate, tartrate, ascorbate, or phosphate, and metal complexes of iron or zinc.
The peptides are preferably administered
parenterally, i.e., subcutaneously, intravenously,
intramuscularly, intraperitoneally or percutaneously. For these modes of administration, the peptides will normally be combined with a pharmaceutically acceptable carrier, such as water, or isotonic saline. Alternatively, the peptides may be administered orally in the form of tablets or capsules, which contain the appropriate binders, lubricants and the like.
The amount of peptide needed per composition, and/or unit dosage can readily be determined by reference and comparison to known compositions and dosage forms currently in use for GRF peptides. In general terms, however, the dosage range will be between 50 ng - 5 μg/kg of body weight of the host. The dose will depend upon the mode
of administration and the intended result. However, such manipulations are well within the ability of one skilled in the art.
5.3. THERAPEUTIC USES
The synthetic peptides are useful in any
situation in which direct administration of growth hormone would be desired. For veterinary use, this includes for example administration to livestock, such as cattle, chickens, turkeys, pigs, goats, fish, and the like, both to promote growth and also to alter or improve the ratio of protein (muscle) to fat in such animals.
The peptides are also useful for the treatment of growth hormone deficiency-related disorders, such as pituitary dwarfism. Various other metabolic or
developmental processes such as wound healing are also affected by growth hormone, and may thus benefit by
administration of the present GRF analogues. Alternate uses of these peptides will be readily recognized by the skilled artisan.
Those peptides of the invention m. which one or more of the proposed Ala substitutions are combined with
Arg2 are GRF antagonists and may therefore be used in treatment of conditions caused by excess growth hormone. An example of such a condition is acromegaly, which results in abnormal enlargement of the bones of the face and.
extremities, among other symptoms.
6. EXAMPLES
6.1. SYNTHESIS OF ANALOGUES
6.1.1. [Ala8]-GRF(1-29)-methylbenzhydrylamme Resin
Benzhydrylamine-polystyrene resin (Advanced ChemTech,
Inc.) (1.25 g, 0.5 mmole) in the chloride ion form is placed in the reaction vessel of an Advanced ChemTech peptide synthesizer programmed to perform the following reaction
cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times for 1 and 15 min each);
(c) methylene chloride; (d) ethanol; (e) methylene chloride;
(f) 10% disopropylethylamine in methylene chloride.
The neutralized resin is stirred with Boc-NG- tosyl-
Arg and diisopropylcarbodiimide (1.5 mmole each) in
methylene chloride for 1 h and the resulting amino acid resin is then cycled through steps (a) to (f) in the above wash program. The following amino acids (1.5 mmole) are then coupled successively by the same procedure, except that Gin and Asn were coupled in the presence of 1.5 mmole of 1- hydroxybenzotriazole:
Boc-Ser(Bzl), Boc-Met, Boc-Asp(chx), Boc-Gln, Boc-Leu, Boc- Lys(2-Cl-Z), Boc-Arg(Tos), Boc-Ala, Boc-Ser(Bzl), Boc-Leu,
Boc-Gln, Boc-Gly, Boc-Leu, Boc-Val, Boc-Lys(2-Cl-Z), Boc-
Arg(Tos), Boc-Tyr(2-Br-Z), Boc-Ser(Bzl), Boc-Ala, Boc-
Thr(Bzl), Boc-Phe, Boc-Ile, Boc-Ala, Boc-Asp, Boc-Ala, Boc- Tyr(2-Br-Z). After removal of the last Boc group and washing and drying, the completed resin weighed 2.5 g.
6.1.2. Ala8GRF(1-29)NH2
The resin described in Section 9.1.1. (2.5 g, 0.5 mmole) is mixed with p-cresol (5 ml), dithiothreitol (100 mg) and anhydrous hydrogen fluoride (35 ml) at ) ºC and stirred for 45 min. Excess hydrogen fluoride is evaporated rapidly under a stream of dry nitrogen and free peptide precipitated and washed with ether. The crude peptide is then dissolved in a minimum volume of 2 M acetic acid and eluted on a column (2.5 x 100 cm) of Sephadex G-50 using the same solvent. Fractions containing a major component by uv absorption and thin layer chromatography are then pooled, evaporated to a small volume and applied to a column (2.5 x
50 cm) of Vydac octadecylsilane silica (10-15 μK) .
This is eluted with a linear gradient of 10-45% acetonitrile in 0.1% trifluoroacetic acid in water.
Fractions are examined by thin layer chromatography and analytical high performance liquid chromatography and pooled to give maximum purity. Repeated lyophilization of the solution from water gives the product as a white, fluffy powder.
The product is found to be homogeneous by HPLC and
TLC. Amino acid analysis of an acid hydrolysate confirms the composition of the octapeptide. 6.1.3. [Ala8,15]-GRF(1-29)-methylbenzhydrylamιne Resm
Benzhydrylamine-polystyrene resin (Advanced ChemTech,
Inc.) (1.25 g, 0.5 mmole) in the chloride ion form is placed in the reaction vessel of an Advanced ChemTech peptide synthesizer programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trufluoroacetic acid in methylene chloride (2 times for 1 and 15 min each);
(c) methylene chloride; (d) ethanol; (e) methylene chloride;
(f) 10% diisopropylethylamine in methylene chloride.
The neutralized resin is stirred with Boc-NG- tosyl-
Arg and diisopropylcarbodiimide (1.5 mmole each) in
methylene chloride for 1 h and the resulting amino acid resin is then cycled through steps (a) to (g) in the above wash program. The following amino acids (1.5 mmole) are then coupled successively by the same procedure, except that
Gin and Asn were coupled in the presence of 1.5 mmole of 1- hydroxybenzotriazole:
Boc-Ser(Bzl), Boc-Met, Boc-Asp(chx), Boc-Gln, Boc-Leu, Boc-
Lys(2-Cl-Z), Boc-Arg(Tos), Boc-Ala, Boc-Ser(Bzl), Boc-Leu,
Boc-Gln, Boc-Ala, Boc-Leu, Boc-Val, Boc-Lys(2-Cl-Z), Boc-
Arg(Tos), Boc-Tyr(2-Br-Z), Boc-Ser(Bzl), Boc-Ala, Boc- Thr(Bzl), Boc-Phe, Boc-Ile, Boc-Ala, Boc-Asp, Boc-Ala, Boc- Tyr(2-Br-Z). After removal of the last Boc group and washing and drying, the completed resin weighed 2.6 g.
6.1.4. Ala8,15-GRF(1-29)NH2
The resin described in Section 6.1.3. (2.6 g, 0.5 mmole) was subjected to cleavage with hydrogen fluoride and column purification as described in Section 6.1.2. Repeated lyophilization of the solution from water gives the desired product as a white, fluffy powder.
The product is found to be homogeneous by hplc and tic. Amino acid analysis of an acid hydrolysate confirms the composition of the octapeptide.
In a similar manner, the following peptides were also made:
Aib8, Ala15-GRF(1-29)NH
Ala8'15, Glu25, Leu25'2 -GRF(1-29)NH
D-Ala2, Leu7, Ala8'15, Glu25, Leu26' -GRF(1-29)NH2
D-Ala21, Ala8'15, Glu25, Leu26,27-GRF(1-29)NH2
Ala8'9'15, Glu25, Leu26'27-GRF(1-29)NH2
D-Ala2, Ala8,15-GRF(1-29)NH2
D-Ala21, Ala8'9'15-GRF(1-29)NH2
Ala7'8'9'15-GRF(1-29)NH2
Ala8'9'10'15-GRF(1-29)NH
D-Arg2, Ala8,1-GRF(1-29)NH2
6.2. BIOLOGICAL ACTIVITY
A number of the peptides of the present invention were tested in an in vitro assay for their utility to stimulate relase of growth hormone from pituitary cells.
6.2.1. Pituitary Cell Dispersion
Anterior pituitaries from adult male rats weighing 200-250 g and housed under controlled conditions
(lights on from 0500-1900 h), were dispersed using aseptic technique by a previously described trypsin/DNase method (Heiman et al., Endocrinology 116:410-415, 1985) derived
from other methods (Ben-Jonathan, Meth. Enzymol. 103:249- 257, 1983; Hoefer et al., Mol. Cell. Endocrinol. 35:229-235, 1984).
6.2.2. Cell Culture
The dispersed cells were diluted with sterile- filtered Dulbecco's modified Eagle medium (MEM) (Gibco
Laboratories (GIBCO), Grand Island, NY), which was
supplemented with 2.5% fetal calf serum (GIBCO), 3% horse serum (GIBCO), 10% fresh rat serum (stored on ice for no longer than 1 h) from the pituitary donors, 1% MEM
nonessential amino acids (GIBCO), gentamycin (10 ng/ml;
Sigma) and Nystatin (10,000 U/ml; GIBCO). The cells were counted with a hemacytometer (approximately 2,000,000 cells per pituitary) and randomly plated at a density of 200,000 cells per well (Costar cluster 24; Rochester Scientific, Rochester, NY). The plated cells were maintained in the above Dulbecco's medium in a humidified atmosphere of 95% air and 5% CO2 at 37ºC for 96 h.
6.2.3. In Vitro Incubation
In preparation for a hormone challenge, the cells were washed 3 X with medium 199 (GIBCO) to remove old medium and floating cells. Each dose of secretagogue (diluted in siliconized test tubes) was tested in quadruplicate wells in a total volume of 1 ml medium 199 containing 1% BSA
(fraction V; Sigma Chemical, St. Louis, MO). Cells were pulsed in the presence of 0.1 nM somatostatin to maintain control levels within narrow limits and to increase the ratio of maximally stimulated levels to basal secretory levels without adding additional growth factors or
glucocorticoids. After 3 h at 37ºC in an air/carbon dioxide atmosphere (95/5%), the medium was removed and stored at -20ºC until assayed for hormone content.
6.2.4. GH RIA
GH in plasma and media was measured by a standard double antibody RIA using components generously supplied by
NIDDK and the National Hormone and Pituitary Program.
University of Maryland School of Medicine.
6.2.5. Results
Potencies were calculated by 4-point assay according to the method described by Pugsley (Endocrinology 39: 161-176, 1946). The results of these tests are presented in Table 1. As can be seen from these data, the combination of Ala at the 8 with Ala at the 15 position greatly
increases the efficacy of the peptide relative to the analogue with Ala 15 alone. Similarly, addition of an Ala9 and or D-Ala 2 also enhances the peptides GRF activity. On the other hand, substitution of Ala at other sites in the
N-terminal region, i.e., at positions 7 and 10 have an essentially detrimental effect when combined with the
Ala 8,9,15 combination.
Potencies were calculated by 4-point assay. Values are the means + sem. The value in parentheses is the number of independent experiments using multiple doses of analogue used in calculating the mean potency. A GRF(1-29)NH2 standard (potency=1) was contained in each assay. For further details, see Murphy and Coy, Peptide Research
1(1):36-41(1988).
Claims (64)
1. Peptides comprising the sequence
R1 - R2 - R3 - Ala - He - Phe - R7 - R8 - R9 - R 10 - Arg - R12 - R13 - R14 - R15 - Gln - R17 - R18 - Ala - Arg - R21
Leu - R23 - R24 - R25 - R26 - R27 - R28 - R29 wherein R1 is des-amino-Tyr, or A-R1 , in which A is lower alkyl, lower cycloalkyl, benzyl or lower acyl and R1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His, or D-His with or without a Cα Me or NαMe substituent
R2 is Ala, D-Ala, D-NMA, or D-Arg;
R3 is Asp or D-Asp;
R7 is Thr, Aib, Leu, Trp, β-Nal, or p-X-Phe, in which
X = H, F, Cl, Br, NO2 or Me;
R8 is Ala, Aib, Leu, Trp, β-Nal, or p-X-Phe, in which X is
H, F, Cl, Br, NO2 or Me;
R9 is Ser, Ala, Aib, Leu, Trp, β-Nal or p-X-Phe, in which
X is H, F, Cl, Br, NO2 or Me
R10 is Tyr or D-Tyr
R12 and R21 are Lys, Arg, or Nξ-B-Lys, in which B is lower alkyl or cycloalkyl
R13 is Ile or Val
R14 is is Leu or D-Leu
R15 Gly, Ala, Leu, Asn, Gln or Aib
R17 is Leu or D-Leu
R18 is Tyr or Ser
R23 is Leu or d-Leu
R24 His or Gin
R25 is Glu, Asp, D-Glu or D-Asp
R26 is Ile or Leu
R27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva, or Val
R28 is Asn, Ser or des R2
R29 is Arg, D-Arg or des R29; and pharmaceutically acceptable salts thereof.
2. The peptides of Claim 1 in which R8 is Ala.
3. The peptide of Claim 2 in which R15 is Ala.
4. The peptide of Claim 3 in which R9 is Ala.
5. The peptide of any one of Claims 1-4 in which R2 is D-Ala.
6. The peptide of Claim 4 in which R25 is Glu.
7. The peptide of Claim 6 in which each of R26 and R 27 is Leu.
8. The peptide of Claim 5 in which R25 is Glu.
9. The peptide of Claim 5 in which each of R26 and R 27 is Leu.
10. The peptide of Claim 1 which comprises Ala8
-GRF (1-29).
11. The peptide of Claim 1 which comprises
Ala8'15-GRF (1-29).
12. The peptide of Claim 1 which comprises
Ala8'9'15-GRF (1-29).
13. The peptide of Claim 1 which comprises
D-Ala2, Ala8'15-GRF (1-29).
14. The peptide of Claim 1 which comprises
D-Ala2, Ala8'9,15-GRF (1-29).
15. The peptide of Claim 1 which comprises
D-Ala2, Ala8'15, Glu25, Leu26'27-GRF (1-29).
16. The peptide of Claim 1 in which R2 is D-Arg.
17. The peptide of Claim 16 in which R2 is Ala.
18. The peptide of Claim 16 in which R15 is Ala.
19. The peptide of Claim 17 in which R1 5 is Ala.
20. The peptide of Claim 19 in which R9 is Ala.
21. The peptide of Claim 20 in which R25 is Glu.
22. The peptide of Claim 21 in which each of R26 and R 27 is Leu.
23. The peptide of Claim 16 which comprises
D-Arg2, Ala8-GRF (1-29)
24. The peptide of Claim 16 which comprises D-Arg2, Ala8,15-GRF (1-29).
25. The peptide of Claim 16 which comprises
D-Arg2, Ala8,9,15-GRF (1-29).
26. A pharmaceutical composition comprising an effective amount of a peptide comprising the sequence
R1 - R2 - R3 - Ala - Ile - Phe - R7 - R8 - R9 - R10 - Arg - R12 - R13 - R14 - R15 - Gln - R17 - R18 - Ala - Arg - R21 - Leu - R23 - R24 - R25 - R26 - R27 - R28 - R29 wherein R1 is des-amino-Tyr, or A-R1 , in which A is lower alkyl, lower cycloalkyl, benzyl or lower acyl and R1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His, or D-His with or without a CαMe or NαMe substituent
R2 is Ala, D-Ala, D-NMA, or D-Arg;
R3 is Asp or D-Asp;
R7 is Thr, Ala, Aib, Leu, Trp, β-Nal, or p-X-Phe, in which
X = H, F, Cl, Br, NO2, or Me;
R8 is Ala, Aib, Leu , Trp, β-Nal , or p-X-Phe, in which X is
H, F, Cl , Br, NO2, or Me;
R9 is Ser, Ala, Aib, Leu, Trp, β-N al or p-X-Phe, in which
X is H, F, Cl, Br, NO2, or Me
R10 is Tyr or D-Tyr
R12 and R21 are Lys, Arg, or Nξ-B-Lys, in which B is lower alkyl or cycloalkyl
R13 is Ile or Val
R14 is is Leu or D-Leu
R15 Gly, Ala, Leu, Asn, Gin or Aib
R 17 is Leu or D-Leu
R 18 is Tyr or Ser
R23 is Leu or d-Leu
R24 His or Gln
R25 is Glu, Asp, D-Glu or D-Asp
R26 is Ile or Leu
R27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva, or Val
R28 is Asn, Ser or des R28
R29 is Arg, D-Arg or des R29;
and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier.
27. The composition of Claim 26 in which R8 is
Ala.
28. The composition of Claim 27 in which R1 5 is Ala.
29. The composition of Claim 29 in which R9 is
Ala.
30. The composition of any one of Claims 26-29 in which R2 is D-Ala.
31. The composition of Claim 29 in which R25 isGlu.
32. The composition of Claim 29 in which each of R26 and R27 is Leu.
33. The composition of Claim 30 in which R25 is
Glu.
34. The composition of Claim 30 in which each of
R26 and R27 is Leu.
35. The composition of Claim 26 in which the peptide comprises Ala8-GRF(1-29).
36. The composition of Claim 26 in which the peptide comprises Ala8,15-GRF(1-29).
37. The composition of Claim 26 in which the peptide comprises Ala8,9,15 GRF(1-29).
38. The composition of Claim 26 in which the peptide comprises D-Ala2, Ala8-GRF(1-29).
39. The composition of Claim 26 in which the peptide comprises D-Ala2, Ala8,5-GRF(1-29).
40. The composition of Claim 26 in which the peptide comprises D-Ala2, D-Ala2 Ala8'9'15 GRF(1-29).
41. The composition of Claim 26 in which the peptide comprises D-Ala2, Ala8'15, Glu25, Leu26'27 GRF(1- 29).
42. The composition of Claim 26 in which R2 is
D-Arg.
43. The composition of Claim 42 in which R8 is
Ala.
44. The composition of Claim 26 in which R15 is
Ala.
45. The composition of Claim 42 in which R 15 is
Ala.
46. The composition of Claim 45 in which the R9 is Ala.
47. The composition of Claim 46 in which the R25 is Glu.
48. The composition of Claim 47 in which each of
R26 and R27 is Leu.
49. The composition of Claim 42 in which the peptide comprises D-Arg 2, Ala8 GRF(1-29).
50. The composition of Claim 42 in which the peptide comprises D-Arg2, Ala8'15 GRF(1-29).
51. The composition of Claim 42 in which the peptide comprises D-Arg2, Ala8'9'15 GRF(1-29).
52. A method of increasing production of growth hormone in an individual in need of such treatment which comprises administering to the individual an effectiveamount of the peptide of Claim 1.
53. The method of Claim 52 in which the individual is a mammal.
54. The method of Claim 53 in which the
individual is human.
55. The method of any one of Claims 52-54 in which the dosage is from about 5 μg - 5 μg/kg of body weight.
56. The method of Claim 52 in which the peptide is used to treat pituitary dwarfism.
57. The method of Claim 52 in which the peptide is used to enhance milk production in livestock.
58. The method of Claim 52 in which the peptide is used to enhance growth of livestock.
59. The method of Claim 52 in which the peptide is used to enhance the ratio of protein to fat in an animal.
60. The method of any one of Claims 58-60 in which the livestock is cattle or pigs.
61. A method for decreasing the production of growth hormone in an individual in need of such treatment which comprises administering to the individual an effective amount of the peptide of Claim 16.
62. The method of Claim 61 in which the
individual is human.
63. The method of Claim 61 or 62 in which the dosage is from about 5 μg - 5 μg/kg of body weight.
64. The method of anyone of Claims 62-64 in which the peptide is used to treat acromegaly.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51905490A | 1990-05-04 | 1990-05-04 | |
US519054 | 1990-05-04 | ||
PCT/US1991/003053 WO1991016923A1 (en) | 1990-05-04 | 1991-04-30 | Novel synthetic grf analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7882291A true AU7882291A (en) | 1991-11-27 |
AU651976B2 AU651976B2 (en) | 1994-08-11 |
Family
ID=24066591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU78822/91A Expired - Fee Related AU651976B2 (en) | 1990-05-04 | 1991-04-30 | Novel synthetic GRF analogs |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0527914A4 (en) |
JP (1) | JPH06502618A (en) |
AU (1) | AU651976B2 (en) |
CA (1) | CA2082059A1 (en) |
WO (1) | WO1991016923A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262519A (en) * | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
WO1994011397A1 (en) * | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
WO1994011396A1 (en) * | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
US5550212A (en) * | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
CA2158782C (en) * | 1994-09-23 | 2010-01-12 | Pierrette Gaudreau | Marker for growth hormone-releasing factor receptors |
CA2218173A1 (en) * | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
US6458764B1 (en) * | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
US5942489A (en) * | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
US6057422A (en) * | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
US8691942B2 (en) | 2008-03-28 | 2014-04-08 | University Of Miami | N- and C- terminal substituted antagonistic analogs of GH-RH |
CA2718146C (en) * | 2008-03-28 | 2016-09-20 | The University Of Miami | Novel n- and c-terminal substituted antagonistic analogs of gh-rh |
KR101642363B1 (en) | 2008-06-12 | 2016-07-25 | 입센 바이오이노베이션 리미티드 | Suppression of neuroendocrine diseases |
CN102083451A (en) | 2008-06-12 | 2011-06-01 | 赛恩泰新公司 | Suppression of cancers |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
EP3920961A4 (en) | 2019-02-08 | 2022-12-14 | United States Government as represented by the Department of Veterans Affairs | Growth hormone-releasing hormone antagonists and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649131A (en) * | 1984-09-24 | 1987-03-10 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
US4689318A (en) * | 1985-08-29 | 1987-08-25 | The Salk Institute For Biological Studies | GRF analogs |
IL86102A (en) * | 1987-05-11 | 1994-04-12 | Univ Tulane | Alkylated growth hormone-releasing peptides and use thereof |
US5262519A (en) * | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
-
1991
- 1991-04-30 JP JP3509839A patent/JPH06502618A/en active Pending
- 1991-04-30 WO PCT/US1991/003053 patent/WO1991016923A1/en not_active Application Discontinuation
- 1991-04-30 EP EP19910909888 patent/EP0527914A4/en not_active Withdrawn
- 1991-04-30 CA CA002082059A patent/CA2082059A1/en not_active Abandoned
- 1991-04-30 AU AU78822/91A patent/AU651976B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0527914A1 (en) | 1993-02-24 |
WO1991016923A1 (en) | 1991-11-14 |
EP0527914A4 (en) | 1993-08-11 |
CA2082059A1 (en) | 1991-11-05 |
AU651976B2 (en) | 1994-08-11 |
JPH06502618A (en) | 1994-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5847066A (en) | Analogs of growth hormone-releasing factor | |
FI92210C (en) | Process for preparing pharmaceutically useful GRF analogues | |
US5861379A (en) | Chimeric fatty body-pro-GRF analogs with increased biological potency | |
AU651976B2 (en) | Novel synthetic GRF analogs | |
US5084555A (en) | An octapeptide bombesin analog | |
US7632811B2 (en) | Analogs of parathyroid hormone | |
US6307017B1 (en) | Octapeptide bombesin analogs | |
US20070299009A1 (en) | Analogs of parathyroid hormone | |
JP2001527507A (en) | Improved cyclic CRF antagonist | |
FI87080C (en) | FREQUENCY REARING FOR GRF ANALOGUE | |
CA1268898A (en) | Growth hormone-releasing peptides and method of treating mammals therewith | |
US5416073A (en) | Growth hormone-releasing peptides and method of treating animals, therewith | |
WO2004027064A2 (en) | Ghrh analogues | |
US6020311A (en) | GRF analogs with increased biological potency | |
EP1133522B1 (en) | Antagonistic analogs of gh-rh inhibiting igf-i and -ii | |
US4734399A (en) | Growth hormone releasing factor analogs | |
WO1997042223A9 (en) | hGH-RH(1-29)NH2 ANALOGUES HAVING ANTAGONISTIC ACTIVITY | |
CA1271600A (en) | Growth hormone-releasing peptides and method of treating mammals therewith | |
MXPA06001369A (en) | Antagonistic analogs of gh-rh (2003). | |
US5112808A (en) | Alkylated hormone-releasing peptides and method of treatig mammals therewith | |
EP0307860B1 (en) | Cyclic GRF-analogs | |
JP2678993B2 (en) | Novel alkylated growth hormone releasing peptides and methods of treating mammals therewith | |
NZ227770A (en) | Growth hormone releasing factor (grf) peptide containing a cysteic acid residue in position 3 or 25 | |
AU2003269631B2 (en) | GHRH analogues |